---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-19T10:00:40.354346'
end_time: '2026-01-19T10:07:33.511505'
duration_seconds: 413.16
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: HAP1
  gene_symbol: APEX1
  uniprot_accession: P27695
  protein_description: 'RecName: Full=DNA repair nuclease/redox regulator APEX1; EC=3.1.11.2
    {ECO:0000269|PubMed:11286553, ECO:0000269|PubMed:15380100, ECO:0000269|PubMed:19123919,
    ECO:0000269|PubMed:21762700}; EC=3.1.21.- {ECO:0000269|PubMed:9804799}; AltName:
    Full=APEX nuclease; Short=APEN; AltName: Full=Apurinic-apyrimidinic endonuclease
    1; Short=AP endonuclease 1; Short=APE-1; AltName: Full=DNA-(apurinic or apyrimidinic
    site) endonuclease; AltName: Full=Redox factor-1; Short=REF-1; Contains: RecName:
    Full=DNA repair nuclease/redox regulator APEX1, mitochondrial;'
  gene_info: Name=APEX1; Synonyms=APE, APE1, APEX, APX, HAP1, REF1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the DNA repair enzymes AP/ExoA family.
  protein_domains: AP_endonuc_1. (IPR004808); AP_endonuclease_F1_BS. (IPR020847);
    AP_endonuclease_F1_CS. (IPR020848); Endo/exonu/phosph_ase_sf. (IPR036691); Endo/exonuclease/phosphatase.
    (IPR005135)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 25
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P27695
- **Protein Description:** RecName: Full=DNA repair nuclease/redox regulator APEX1; EC=3.1.11.2 {ECO:0000269|PubMed:11286553, ECO:0000269|PubMed:15380100, ECO:0000269|PubMed:19123919, ECO:0000269|PubMed:21762700}; EC=3.1.21.- {ECO:0000269|PubMed:9804799}; AltName: Full=APEX nuclease; Short=APEN; AltName: Full=Apurinic-apyrimidinic endonuclease 1; Short=AP endonuclease 1; Short=APE-1; AltName: Full=DNA-(apurinic or apyrimidinic site) endonuclease; AltName: Full=Redox factor-1; Short=REF-1; Contains: RecName: Full=DNA repair nuclease/redox regulator APEX1, mitochondrial;
- **Gene Information:** Name=APEX1; Synonyms=APE, APE1, APEX, APX, HAP1, REF1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the DNA repair enzymes AP/ExoA family.
- **Key Domains:** AP_endonuc_1. (IPR004808); AP_endonuclease_F1_BS. (IPR020847); AP_endonuclease_F1_CS. (IPR020848); Endo/exonu/phosph_ase_sf. (IPR036691); Endo/exonuclease/phosphatase. (IPR005135)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "APEX1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'APEX1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **APEX1** (gene ID: HAP1, UniProt: P27695) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P27695
- **Protein Description:** RecName: Full=DNA repair nuclease/redox regulator APEX1; EC=3.1.11.2 {ECO:0000269|PubMed:11286553, ECO:0000269|PubMed:15380100, ECO:0000269|PubMed:19123919, ECO:0000269|PubMed:21762700}; EC=3.1.21.- {ECO:0000269|PubMed:9804799}; AltName: Full=APEX nuclease; Short=APEN; AltName: Full=Apurinic-apyrimidinic endonuclease 1; Short=AP endonuclease 1; Short=APE-1; AltName: Full=DNA-(apurinic or apyrimidinic site) endonuclease; AltName: Full=Redox factor-1; Short=REF-1; Contains: RecName: Full=DNA repair nuclease/redox regulator APEX1, mitochondrial;
- **Gene Information:** Name=APEX1; Synonyms=APE, APE1, APEX, APX, HAP1, REF1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the DNA repair enzymes AP/ExoA family.
- **Key Domains:** AP_endonuc_1. (IPR004808); AP_endonuclease_F1_BS. (IPR020847); AP_endonuclease_F1_CS. (IPR020848); Endo/exonu/phosph_ase_sf. (IPR036691); Endo/exonuclease/phosphatase. (IPR005135)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "APEX1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'APEX1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **APEX1** (gene ID: HAP1, UniProt: P27695) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status update: We verified identity and gathered recent literature (2023–2025), then synthesized function, mechanisms, localization, signaling roles, regulation, disease relevance, and translational applications. Where high‑resolution enzymology (e.g., Mg2+ coordination, specific catalytic residues beyond E96) or subcellular import (mitochondrial MIA) were not present in the retrieved 2023–2025 sources, we note limitations and cite available evidence.

Comprehensive research report: APEX1 (APE1/Ref‑1) — human, UniProt P27695

Identity verification and nomenclature
- Target matches the user-provided identity: Human APEX1 encoding APE1/Ref‑1, also known as APE, APEX, HAP1, REF‑1. Literature in 2023–2025 consistently uses APE1/APEX1/Ref‑1 for the same human protein central to base excision repair (BER) and redox regulation of transcription factors (TFs) (kim2023backupbaseexcision pages 1-2, yang2024roleofape1 pages 2-4).
- Family/domains: Described across sources as the major human AP endonuclease of BER with additional exonuclease and 3′-end processing activities, matching the AP/ExoA enzyme family annotation provided (zhao2024distinctregulationof pages 2-4).

Key concepts and current mechanistic understanding
- Primary enzymatic roles in BER:
  - AP endonuclease: The principal human enzyme that incises DNA at abasic (AP) sites and coordinates downstream BER, often with PARP1, XRCC1, and DNA polymerase β (kim2023backupbaseexcision pages 1-2, yang2024roleofape1 pages 2-4).
  - 3′-end processing and exonuclease: APE1 also performs 3′→5′ exonuclease–mediated end resection at single‑strand breaks (SSBs) and removes 3′ blocking groups via 3′‑phosphodiesterase activity, thereby promoting ATR–Chk1 signaling and SSB repair (zhao2024distinctregulationof pages 2-4).
  - Redundancy/backup: Although APE1 is the major AP endonuclease, human cells can repair some AP analogs without APE1 via backup pathways (e.g., NTHL1‑dependent β‑elimination), demonstrating BER redundancy in vivo (kim2023backupbaseexcision pages 1-2, kim2023backupbaseexcision pages 2-4).
- Redox co‑regulator (Ref‑1): APE1’s redox function reduces specific cysteines on TFs (e.g., HIF‑1α, NF‑κB, AP‑1, STAT3, p53), enhancing DNA binding and transcription. Key cysteines implicated include Cys65, Cys93, and Cys99; redox activity can be pharmacologically inhibited (yang2024roleofape1 pages 2-4, piscone2025targetingthe8oxodg pages 6-7).
- DDR signaling at SSBs and ATM activation:
  - Defined SSB structures directly activate ATM in cell‑free systems; APE1 is necessary and upstream for SSB‑induced ATM signaling (phosphorylation of ATM, Nbs1, Mre11, γH2AX). APE1 promotes recruitment of ATM and MRN and contributes via its 3′→5′ exonuclease activity (zhao2024distinctregulationof pages 4-5, zhao2024distinctregulationof pages 5-6).
  - APE1 also directly stimulates ATM kinase activity through oligomerization mediated by its N‑terminal disordered motif (NT34/NT33). Lysines K25/K26/K33 are required for oligomerization and ATM activation; mutants (e.g., 3KA) fail to activate ATM (zhao2024distinctregulationof pages 8-10, zhao2024distinctregulationof pages 10-11, zhao2024distinctregulationof pages 1-2).

Catalytic/structural determinants
- Residue dependence evidenced in recent studies:
  - E96 (Glu96): CRISPR knock‑in of E96A in PDAC cells selectively reduces endonuclease activity without altering redox signaling, validating functional separation of APE1 enzymology in cells (Dec 2025 preprint; mechanistic relevance to endonuclease function) (kpenu2025targetingape1endonuclease pages 51-56).
  - N‑terminal oligomerization motif: NT34 and lysines K25/K26/K33 are necessary for oligomer formation and ATM activation in SSB signaling (zhao2024distinctregulationof pages 8-10, zhao2024distinctregulationof pages 10-11, zhao2024distinctregulationof pages 5-6).
- Note: Detailed metal coordination (e.g., Mg2+ site and Asp210) were not captured in retrieved 2023–2025 evidence; older crystallography typically addresses these, but are outside the present evidence set.

Cellular and subcellular localization
- Predominantly nuclear/nucleolar in many contexts, with condition‑dependent relocalization. Under hypoxia, Ref‑1/APE1 accumulates in the nucleus of endothelial cells, consistent with a role in facilitating HIF‑1α‑dependent gene activation; cytoplasmic/nuclear shifts and ectopic cytoplasmic localization are reported in cancers (hartman2025ref‐1redoxactivity pages 15-17, yang2024roleofape1 pages 2-4).
- Interactions with nucleolar proteins (e.g., NPM1) and roles in RNA metabolism further support nucleolar functions (kim2023backupbaseexcision pages 12-13).
- Note: Specific mitochondrial import mechanisms (e.g., MIA pathway) were not present in the retrieved 2023–2025 sources.

Pathway roles
- BER: Central rate‑limiting endonuclease in short‑patch and long‑patch BER; coordinates with PARP1, XRCC1, and Pol β (yang2024roleofape1 pages 2-4).
- SSB signaling and ATM: APE1 is essential for ATM activation by SSBs, acting both enzymatically (exonuclease‑dependent end processing) and structurally (oligomerization‑dependent ATM stimulation). In Xenopus extracts, SSB‑induced ATM phosphorylation peaks around ~20 minutes and precedes ATR activation (~55–60 minutes) (zhao2024distinctregulationof pages 4-5, zhao2024distinctregulationof pages 2-4, zhao2024distinctregulationof pages 5-6).
- RNA processing/stress responses: APE1 participates in miRNA maturation (e.g., pri‑miR‑221/222) and modulates stress‑granule–related phosphorylation networks in cancer cells (yang2024roleofape1 pages 2-4, kim2023backupbaseexcision pages 12-13).

Recent developments (2023–2024) and latest research
- Backup BER in APEX1‑deficient human cells: Despite loss of AP endonuclease activity in vitro, APEX1‑KO HEK293FT cells repaired an abasic analog and uracil via alternative mechanisms; NTHL1 dependence observed when AP hydrolysis is blocked, defining at least two backup pathways in vivo (Dec 2023) (kim2023backupbaseexcision pages 1-2, kim2023backupbaseexcision pages 2-4).
- Distinct regulation of ATM by SSBs and APE1: A 2024 Nature Communications study established that defined SSBs activate ATM in an APE1‑dependent manner; APE1 is required for ATM/MRN recruitment and can directly stimulate ATM via N‑terminal oligomerization. Pharmacologic APE1 inhibition (AR03) suppressed SSB‑induced ATM signaling (Aug 2024) (zhao2024distinctregulationof pages 4-5, zhao2024distinctregulationof pages 8-10, zhao2024distinctregulationof pages 5-6).
- HIF‑1α regulation and retinal neovascularization: In retinal endothelial and OIR models, Ref‑1 redox activity controls HIF‑1α transcriptional activation and pathological angiogenesis. APX2009 reduced neovascularization after systemic dosing and diminished HIF‑1α reporter activity and VEGFA transcription without altering HIF protein abundance (Feb 2025) (hartman2025ref‐1redoxactivity pages 15-17, hartman2025ref‐1redoxactivity pages 21-22).
- Cancer context: Reviews highlight APE1’s overexpression and functional roles in hepatocellular carcinoma and broader oncology, including interactions with BER factors and TF redox regulation (Sep 2024) (yang2024roleofape1 pages 2-4).

Current applications and real‑world implementations
- Small‑molecule modulation strategies:
  - Redox inhibitors: APX3330 (E3330) and second‑generation analogs (e.g., APX2009, APX2014). Reviews note APX3330 completed a Phase I oncology trial (2017; NCT03375086) and advanced to Phase II for diabetic retinopathy/macular edema; APX2009 exhibits preclinical efficacy in retinal neovascularization (Cells 2025 review; FASEB 2025 mechanistic study) (piscone2025targetingthe8oxodg pages 6-7, hartman2025ref‐1redoxactivity pages 15-17). URL (Cells review): https://doi.org/10.3390/cells14020112 (2025-01). URL (FASEB): https://doi.org/10.1096/fj.202401989rr (2025-02).
  - Indirect BER blockade: Methoxyamine covalently traps AP sites to prevent APE1 incision. Clinical trials have evaluated combinations with alkylators/antimetabolites; outcomes mixed (e.g., some Phase I tolerability, a Phase II glioblastoma trial not meeting pre‑specified response) (piscone2025targetingthe8oxodg pages 6-7). URL: https://doi.org/10.3390/cells14020112 (2025-01).
- Ophthalmology landscape: Broader small‑molecule development for AMD in 2024 is summarized in a pharmacal research review, framing the translational context for anti‑angiogenic approaches beyond anti‑VEGF biologics (though not specific to APE1 inhibitors) (Jun 2024) (fei2024challengesandopportunities pages 25-38).

Expert opinions and analyses from authoritative sources
- DDR signaling insight: Zhao et al. (Nature Communications 2024) provide authoritative mechanistic analysis defining APE1 as a direct activator of ATM at SSBs, integrating enzymatic (exonuclease) and structural (N‑terminal oligomerization) contributions (zhao2024distinctregulationof pages 4-5, zhao2024distinctregulationof pages 8-10, zhao2024distinctregulationof pages 5-6).
- Translational oncology/angiogenesis perspective: Reviews and mechanistic preclinical studies support targeting Ref‑1 redox activity to dampen HIF‑1α–driven programs and angiogenesis, while noting the complexity of dual‑function targeting and potential need for pathway‑specific selectivity (piscone2025targetingthe8oxodg pages 6-7, hartman2025ref‐1redoxactivity pages 15-17, yang2024roleofape1 pages 2-4).

Quantitative statistics and experimental details
- Abasic lesion burden: AP sites occur at an estimated ~5–20 per 10^6 bases per cell per day, underscoring the centrality of BER/APE1 (kim2023backupbaseexcision pages 1-2).
- SSB→ATM kinetics in extracts: ATM phosphorylation peaks around ~20 minutes after SSB introduction; ATR/Chk1 activation follows at ~55–60 minutes (Xenopus HSS system) (zhao2024distinctregulationof pages 4-5).
- Functional separation of activities: E96A knock‑in reduces endonuclease activity while preserving redox function in PDAC models, which lowered tumor burden and metastasis and enhanced sensitivity to temozolomide in vivo (preclinical, 2025) (kpenu2025targetingape1endonuclease pages 51-56).

Post‑translational regulation
- Sirtuin‑mediated deacetylation and interactions: SIRT1 deacetylates APE1 and modulates BER; SIRT6 interacts with APE1 alongside other repair/checkpoint factors, indicative of PTM‑dependent regulation of function and complex assembly (kim2023backupbaseexcision pages 12-13).

Limitations of current evidence set
- High‑resolution catalytic details (e.g., Mg2+ coordination sphere, Asp210 roles) and mitochondrial import specifics were not present in the retrieved 2023–2025 sources used here; we therefore constrained claims to supported recent evidence and highlighted E96 and N‑terminal oligomerization features where directly shown (kpenu2025targetingape1endonuclease pages 51-56, zhao2024distinctregulationof pages 8-10).

Embedded summary artifact
| Domain/Function | Mechanistic highlights | 2023–2025 key findings | Evidence (citation IDs) | Notes/Applications |
|---|---|---|---|---|
| Base excision repair (AP endonuclease) | Incises AP sites, processes 3'-blocking groups (3'-phosphodiesterase) and participates in downstream BER coordination with XRCC1/PARP1/Polβ; essential for AP-site hydrolysis in many contexts. | APE1 remains the principal human AP endonuclease; APEX1 knockout cells reveal viability but engage backup repair routes for some AP analogs, indicating redundant/alternative BER pathways in cells. | (kim2023backupbaseexcision pages 1-2, kim2023backupbaseexcision pages 12-13, kim2023backupbaseexcision pages 2-4) | Targeting endonuclease activity sensitizes tumors to genotoxic agents (preclinical rationale) and motivates selective endonuclease perturbation studies (therapeutic strategy). |
| Single-strand break (SSB) signaling & ATM activation | APE1 exonuclease activity and N-terminal oligomerization recruit/activate ATM at SSBs; N-terminal NT34 motif and lysines (e.g., K25/K26/K33) mediate APE1 oligomerization required for ATM stimulation. | Defined SSB substrates trigger ATM DDR in Xenopus extracts via APE1-dependent recruitment/processing; APE1 oligomerization can directly stimulate ATM kinase activity even in DNA-free assays. | (zhao2024distinctregulationof pages 8-10, zhao2024distinctregulationof pages 10-11, zhao2024distinctregulationof pages 4-5, zhao2024distinctregulationof pages 1-2, zhao2024distinctregulationof pages 2-4, zhao2024distinctregulationof pages 5-6) | Links APE1 catalytic and structural features to DDR signaling (implications for replication stress, therapeutic combination with DDR inhibitors). |
| Redox co-regulator (Ref-1) of transcription factors | Redox-mediated reduction of critical cysteines in TFs (HIF-1α, NF-κB, AP-1, STAT3, p53) enhances DNA binding/transcriptional activation; specific cysteines (Cys65, Cys93, Cys99) implicated in redox activity. | Pharmacologic redox inhibition (APX3330, second-generation APX2009/APX2014 analogs) reduces HIF-1α-driven transcription and retinal neovascularization in preclinical models; clinical development of APX3330 progressed to Phase I/II trials for oncology and retinal disease. | (yang2024roleofape1 pages 2-4, piscone2025targetingthe8oxodg pages 6-7, hartman2025ref‐1redoxactivity pages 15-17, hartman2025ref‐1redoxactivity pages 21-22) | Redox inhibitors are leading translational candidates; redox vs repair selectivity is a central therapeutic consideration. |
| RNA metabolism & stress responses | APE1 participates in RNA processing: endoribonuclease activity, modulation of miRNA maturation, and regulation of stress-granule–associated phosphorylation networks. | Recent studies emphasize APE1 roles in RNA quality control and stress responses; APE1 perturbation alters phosphoproteome and influences stress granule dynamics and cell survival in cancer models. | (kim2023backupbaseexcision pages 12-13, kim2023backupbaseexcision pages 13-15) | Noncanonical RNA functions expand disease-relevant mechanisms beyond DNA repair (possible biomarkers/targets). |
| Subcellular localization & trafficking | Predominantly nuclear/nucleolar with regulated cytoplasmic and mitochondrial pools; interactions (e.g., NPM1) and stimulus-dependent relocalization (hypoxia → nuclear) reported. | Cancer and stress conditions show altered localization (ectopic cytoplasmic APE1 in tumors); hypoxia drives nuclear relocalization linked to HIF-1α transcriptional regulation. | (kim2023backupbaseexcision pages 12-13, yang2024roleofape1 pages 2-4, hartman2025ref‐1redoxactivity pages 15-17) | Localization impacts which APE1 function (repair vs redox vs RNA) predominates and informs targeted delivery strategies. |
| Disease relevance & translational inhibitors | Overexpressed in many cancers; dual repair/redox activities contribute to therapy resistance, angiogenesis, and inflammation; small molecules targeting redox (APX series) and indirect BER blockade (methoxyamine) under development. | APX3330 completed early-phase clinical testing and progressed into trials for diabetic retinopathy; APX2009 shows preclinical efficacy in retinal neovascularization; methoxyamine combinations tested in clinical trials with mixed efficacy. | (piscone2025targetingthe8oxodg pages 6-7, yang2024roleofape1 pages 2-4, hartman2025ref‐1redoxactivity pages 15-17) | Clinical modulation of Ref-1/APE1 aims at anti-angiogenic, cytotoxic sensitization, and anti-inflammatory indications; trial outcomes and biomarker-driven selection remain active areas. |
| Backup/alternative BER pathways & redundancy | Other glycosylases (NTHL1, OGG1, NEILs), APE2, TDP1, PNKP and NER factors (UV-DDB) can process AP or related lesions via β-elimination or coordinated pathways. | APEX1-null human cells can repair certain AP-site analogs via NTHL1-dependent β-elimination and other backup routes, demonstrating cellular redundancy and complexity of BER in vivo. | (kim2023backupbaseexcision pages 1-2, kim2023backupbaseexcision pages 12-13, kim2023backupbaseexcision pages 13-15, kim2023backupbaseexcision pages 2-4) | Redundancy complicates therapeutic targeting of APE1's repair activity and suggests combination strategies or context-specific biomarkers may be required. |


*Table: Concise summary table of APEX1 (APE1/Ref-1) domains/functions, mechanistic highlights, 2023–2025 findings, evidence IDs, and translational notes; useful for quick reference and citation-guided follow-up.*

References (URLs and dates in-text; evidence IDs for claims):
- Kim et al., 2023, IJMS. https://doi.org/10.3390/ijms25010064 (2023-12). BER backup and APE1 essentiality context (kim2023backupbaseexcision pages 1-2, kim2023backupbaseexcision pages 12-13, kim2023backupbaseexcision pages 2-4).
- Zhao et al., 2024, Nature Communications. https://doi.org/10.1038/s41467-024-50836-6 (2024-08). SSB→ATM mechanisms and APE1 oligomerization (zhao2024distinctregulationof pages 4-5, zhao2024distinctregulationof pages 8-10, zhao2024distinctregulationof pages 10-11, zhao2024distinctregulationof pages 2-4, zhao2024distinctregulationof pages 5-6).
- Yang & Sun, 2024, Molecular and Clinical Oncology. https://doi.org/10.3892/mco.2024.2780 (2024-09). Cancer-focused review on APE1 biology and redox TF regulation (yang2024roleofape1 pages 2-4, yang2024roleofape1 pages 1-2).
- Piscone et al., 2025, Cells. https://doi.org/10.3390/cells14020112 (2025-01). Therapeutic targeting overview of 8‑oxodG BER including APX3330 and methoxyamine (piscone2025targetingthe8oxodg pages 6-7).
- Hartman et al., 2025, FASEB J. https://doi.org/10.1096/fj.202401989rr (2025-02). Ref‑1 redox regulation of HIF‑1α and retinal neovascularization; APX2009 effects (hartman2025ref‐1redoxactivity pages 15-17, hartman2025ref‐1redoxactivity pages 21-22).
- Kpenu et al., 2025, Research Square. https://doi.org/10.21203/rs.3.rs-8197122/v1 (2025-12). E96A knock‑in delineating endonuclease role in PDAC biology and therapy response (kpenu2025targetingape1endonuclease pages 51-56).
- Fei et al., 2024, Arch Pharm Res. https://doi.org/10.1007/s12272-024-01503-3 (2024-06). Small‑molecule landscape in AMD (context) (fei2024challengesandopportunities pages 25-38).

References

1. (kim2023backupbaseexcision pages 1-2): Daria V. Kim, Evgeniia A. Diatlova, Timofey D. Zharkov, Vasily S. Melentyev, Anna V. Yudkina, Anton V. Endutkin, and Dmitry O. Zharkov. Back-up base excision dna repair in human cells deficient in the major ap endonuclease, ape1. International Journal of Molecular Sciences, 25:64, Dec 2023. URL: https://doi.org/10.3390/ijms25010064, doi:10.3390/ijms25010064. This article has 4 citations and is from a poor quality or predatory journal.

2. (yang2024roleofape1 pages 2-4): Lei Yang and Zhipeng Sun. Role of ape1 in hepatocellular carcinoma and its prospects as a target in clinical settings (review). Molecular and Clinical Oncology, Sep 2024. URL: https://doi.org/10.3892/mco.2024.2780, doi:10.3892/mco.2024.2780. This article has 0 citations and is from a poor quality or predatory journal.

3. (zhao2024distinctregulationof pages 2-4): Haichao Zhao, Jia Li, Zhongsheng You, Howard D. Lindsay, and Shan Yan. Distinct regulation of atm signaling by dna single-strand breaks and ape1. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50836-6, doi:10.1038/s41467-024-50836-6. This article has 17 citations and is from a highest quality peer-reviewed journal.

4. (kim2023backupbaseexcision pages 2-4): Daria V. Kim, Evgeniia A. Diatlova, Timofey D. Zharkov, Vasily S. Melentyev, Anna V. Yudkina, Anton V. Endutkin, and Dmitry O. Zharkov. Back-up base excision dna repair in human cells deficient in the major ap endonuclease, ape1. International Journal of Molecular Sciences, 25:64, Dec 2023. URL: https://doi.org/10.3390/ijms25010064, doi:10.3390/ijms25010064. This article has 4 citations and is from a poor quality or predatory journal.

5. (piscone2025targetingthe8oxodg pages 6-7): Anna Piscone, Francesca Gorini, Susanna Ambrosio, Anna Noviello, Giovanni Scala, Barbara Majello, and Stefano Amente. Targeting the 8-oxodg base excision repair pathway for cancer therapy. Cells, 14:112, Jan 2025. URL: https://doi.org/10.3390/cells14020112, doi:10.3390/cells14020112. This article has 5 citations and is from a poor quality or predatory journal.

6. (zhao2024distinctregulationof pages 4-5): Haichao Zhao, Jia Li, Zhongsheng You, Howard D. Lindsay, and Shan Yan. Distinct regulation of atm signaling by dna single-strand breaks and ape1. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50836-6, doi:10.1038/s41467-024-50836-6. This article has 17 citations and is from a highest quality peer-reviewed journal.

7. (zhao2024distinctregulationof pages 5-6): Haichao Zhao, Jia Li, Zhongsheng You, Howard D. Lindsay, and Shan Yan. Distinct regulation of atm signaling by dna single-strand breaks and ape1. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50836-6, doi:10.1038/s41467-024-50836-6. This article has 17 citations and is from a highest quality peer-reviewed journal.

8. (zhao2024distinctregulationof pages 8-10): Haichao Zhao, Jia Li, Zhongsheng You, Howard D. Lindsay, and Shan Yan. Distinct regulation of atm signaling by dna single-strand breaks and ape1. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50836-6, doi:10.1038/s41467-024-50836-6. This article has 17 citations and is from a highest quality peer-reviewed journal.

9. (zhao2024distinctregulationof pages 10-11): Haichao Zhao, Jia Li, Zhongsheng You, Howard D. Lindsay, and Shan Yan. Distinct regulation of atm signaling by dna single-strand breaks and ape1. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50836-6, doi:10.1038/s41467-024-50836-6. This article has 17 citations and is from a highest quality peer-reviewed journal.

10. (zhao2024distinctregulationof pages 1-2): Haichao Zhao, Jia Li, Zhongsheng You, Howard D. Lindsay, and Shan Yan. Distinct regulation of atm signaling by dna single-strand breaks and ape1. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50836-6, doi:10.1038/s41467-024-50836-6. This article has 17 citations and is from a highest quality peer-reviewed journal.

11. (kpenu2025targetingape1endonuclease pages 51-56): Eyram K. Kpenu, Mahmut Mijiti, Silpa Gampala, Jun Wan, Sheng Liu, Randall S. Wireman, Jacqueline Peil, Dana K. Mitchell, Sanya Haiaty, Rajesh Sardar, Akanksha Sharma, Millie M. Georgiadis, Melissa L. Fishel, and Mark R. Kelley. Targeting ape1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. Research Square, Dec 2025. URL: https://doi.org/10.21203/rs.3.rs-8197122/v1, doi:10.21203/rs.3.rs-8197122/v1. This article has 0 citations.

12. (hartman2025ref‐1redoxactivity pages 15-17): Gabriella D. Hartman, Anbukkarasi Muniyandi, Kamakshi Sishtla, Eyram K. Kpenu, William P. Miller, Bryan A. Kaplan, Leo A. Kim, Sheng Liu, Jun Wan, Xiaoping Qi, Michael E. Boulton, Mark R. Kelley, and Timothy W. Corson. Ref‐1 redox activity regulates retinal neovascularization by modulating transcriptional activation of hif‐1α. The FASEB Journal, Feb 2025. URL: https://doi.org/10.1096/fj.202401989rr, doi:10.1096/fj.202401989rr. This article has 5 citations.

13. (kim2023backupbaseexcision pages 12-13): Daria V. Kim, Evgeniia A. Diatlova, Timofey D. Zharkov, Vasily S. Melentyev, Anna V. Yudkina, Anton V. Endutkin, and Dmitry O. Zharkov. Back-up base excision dna repair in human cells deficient in the major ap endonuclease, ape1. International Journal of Molecular Sciences, 25:64, Dec 2023. URL: https://doi.org/10.3390/ijms25010064, doi:10.3390/ijms25010064. This article has 4 citations and is from a poor quality or predatory journal.

14. (hartman2025ref‐1redoxactivity pages 21-22): Gabriella D. Hartman, Anbukkarasi Muniyandi, Kamakshi Sishtla, Eyram K. Kpenu, William P. Miller, Bryan A. Kaplan, Leo A. Kim, Sheng Liu, Jun Wan, Xiaoping Qi, Michael E. Boulton, Mark R. Kelley, and Timothy W. Corson. Ref‐1 redox activity regulates retinal neovascularization by modulating transcriptional activation of hif‐1α. The FASEB Journal, Feb 2025. URL: https://doi.org/10.1096/fj.202401989rr, doi:10.1096/fj.202401989rr. This article has 5 citations.

15. (fei2024challengesandopportunities pages 25-38): Xiang Fei, Sooyun Jung, Sangil Kwon, Jiweon Kim, Timothy W. Corson, and Seung-Yong Seo. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration. Archives of pharmacal research, 47:538-557, Jun 2024. URL: https://doi.org/10.1007/s12272-024-01503-3, doi:10.1007/s12272-024-01503-3. This article has 8 citations and is from a peer-reviewed journal.

16. (kim2023backupbaseexcision pages 13-15): Daria V. Kim, Evgeniia A. Diatlova, Timofey D. Zharkov, Vasily S. Melentyev, Anna V. Yudkina, Anton V. Endutkin, and Dmitry O. Zharkov. Back-up base excision dna repair in human cells deficient in the major ap endonuclease, ape1. International Journal of Molecular Sciences, 25:64, Dec 2023. URL: https://doi.org/10.3390/ijms25010064, doi:10.3390/ijms25010064. This article has 4 citations and is from a poor quality or predatory journal.

17. (yang2024roleofape1 pages 1-2): Lei Yang and Zhipeng Sun. Role of ape1 in hepatocellular carcinoma and its prospects as a target in clinical settings (review). Molecular and Clinical Oncology, Sep 2024. URL: https://doi.org/10.3892/mco.2024.2780, doi:10.3892/mco.2024.2780. This article has 0 citations and is from a poor quality or predatory journal.

## Citations

1. zhao2024distinctregulationof pages 2-4
2. kim2023backupbaseexcision pages 12-13
3. fei2024challengesandopportunities pages 25-38
4. kim2023backupbaseexcision pages 1-2
5. zhao2024distinctregulationof pages 4-5
6. kim2023backupbaseexcision pages 2-4
7. zhao2024distinctregulationof pages 5-6
8. zhao2024distinctregulationof pages 8-10
9. zhao2024distinctregulationof pages 10-11
10. zhao2024distinctregulationof pages 1-2
11. kim2023backupbaseexcision pages 13-15
12. https://doi.org/10.3390/cells14020112
13. https://doi.org/10.1096/fj.202401989rr
14. https://doi.org/10.3390/ijms25010064
15. https://doi.org/10.1038/s41467-024-50836-6
16. https://doi.org/10.3892/mco.2024.2780
17. https://doi.org/10.21203/rs.3.rs-8197122/v1
18. https://doi.org/10.1007/s12272-024-01503-3
19. https://doi.org/10.3390/ijms25010064,
20. https://doi.org/10.3892/mco.2024.2780,
21. https://doi.org/10.1038/s41467-024-50836-6,
22. https://doi.org/10.3390/cells14020112,
23. https://doi.org/10.21203/rs.3.rs-8197122/v1,
24. https://doi.org/10.1096/fj.202401989rr,
25. https://doi.org/10.1007/s12272-024-01503-3,